Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06567314
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To learn if ivonescimab can help to control advanced cSCC. The safety and effects of ivonescimab will also be studied.

Key Dates

Start date
Dec 2, 2024
Status verified
Jun 2026
Primary completion
Sep 1, 2028
Completion
Sep 1, 2030

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ivonescimab
    Participants found to be eligible to take part in this study, you will receive ivonescimab by vein over about 1-2 hours on Day 1 of each 21-day cycle (1 time every 3 weeks).

Primary Outcome Measure

Safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Aung Naing, MD
[email protected]
713-563-3885
Aung Naing, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By condition
Skin cancer
By specialty
OncologySkin cancerDermatology
By research site
MD Anderson Cancer Center· Houston, TX

Related Studies